{
    "ticker": "MYGN",
    "name": "Myriad Genetics, Inc.",
    "description": "Myriad Genetics, Inc. is a molecular diagnostic company that plays a crucial role in personalized medicine and genetic testing. Founded in 1991, Myriad focuses on discovering and commercializing proprietary tests that can help assess risk, guide treatment decisions, and monitor patient outcomes for a variety of diseases, particularly cancer. The company is well-known for its groundbreaking tests like the BRACAnalysis, which evaluates an individual's risk for breast and ovarian cancers by analyzing mutations in the BRCA1 and BRCA2 genes. Additionally, Myriad offers a comprehensive portfolio of tests that cover a range of conditions, including hereditary cancer, mental health, and autoimmune diseases. By leveraging advanced genomic insights, Myriad aims to empower patients and healthcare providers with critical information to optimize treatment strategies. The company is dedicated to advancing the field of genetic testing and improving healthcare outcomes through innovation and research. With a commitment to ethical practices and patient-centric care, Myriad Genetics stands at the forefront of the evolving landscape of precision medicine.",
    "industry": [
        "Healthcare",
        "Biotechnology",
        "Diagnostics"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "1991",
    "website": "https://www.myriad.com",
    "ceo": "Paul J. Diaz",
    "social_media": {
        "twitter": "https://twitter.com/myriadgenetics",
        "linkedin": "https://www.linkedin.com/company/myriad-genetics/"
    },
    "investor_relations": "https://investors.myriad.com",
    "key_executives": [
        {
            "name": "Paul J. Diaz",
            "position": "CEO"
        },
        {
            "name": "Michele H. Greer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "BRACAnalysis",
                "MyRisk"
            ]
        },
        {
            "category": "Mental Health",
            "products": [
                "GeneSight"
            ]
        },
        {
            "category": "Autoimmune Diseases",
            "products": [
                "Vectra DA"
            ]
        }
    ],
    "seo": {
        "meta_title": "Myriad Genetics, Inc. | Personalized Molecular Diagnostics",
        "meta_description": "Explore Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine. Learn about Myriad's innovative tests and commitment to advancing healthcare.",
        "keywords": [
            "Myriad Genetics",
            "Genetic Testing",
            "Personalized Medicine",
            "Oncology Diagnostics",
            "BRACAnalysis",
            "GeneSight"
        ]
    },
    "faq": [
        {
            "question": "What does Myriad Genetics do?",
            "answer": "Myriad Genetics specializes in molecular diagnostics and offers tests that help assess genetic risks and guide treatment decisions."
        },
        {
            "question": "Who is the CEO of Myriad Genetics?",
            "answer": "Paul J. Diaz is the CEO of Myriad Genetics, Inc."
        },
        {
            "question": "Where is Myriad Genetics headquartered?",
            "answer": "Myriad Genetics is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "What are Myriad's main products?",
            "answer": "Myriad's main products include BRACAnalysis, MyRisk, GeneSight, and Vectra DA."
        },
        {
            "question": "When was Myriad Genetics founded?",
            "answer": "Myriad Genetics was founded in 1991."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRA",
        "GNMK",
        "ILMN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}